Pfizer Inc. (NYSE:PFE) Shares Sold by Access Financial Services Inc.

Access Financial Services Inc. trimmed its position in Pfizer Inc. (NYSE:PFE) by 15.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 41,683 shares of the biopharmaceutical company’s stock after selling 7,835 shares during the period. Access Financial Services Inc.’s holdings in Pfizer were worth $1,200,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of PFE. Worth Asset Management LLC acquired a new position in shares of Pfizer in the 1st quarter valued at $29,000. Briaud Financial Planning Inc purchased a new stake in shares of Pfizer in the third quarter valued at approximately $30,000. Sanctuary Wealth Management L.L.C. acquired a new position in Pfizer during the fourth quarter worth $50,000. Mizuho Securities Co. Ltd. acquired a new position in shares of Pfizer during the 3rd quarter worth $34,000. Finally, VisionPoint Advisory Group LLC lifted its position in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

PFE stock opened at $27.75 on Friday. The company has a market capitalization of $157.14 billion, a P/E ratio of 77.08, a PEG ratio of 1.24 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company has a 50-day simple moving average of $27.46 and a 200 day simple moving average of $29.46. Pfizer Inc. has a fifty-two week low of $25.61 and a fifty-two week high of $42.22.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the previous year, the company earned $1.14 earnings per share. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on PFE shares. Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Truist Financial dropped their price objective on Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 14th. Finally, Barclays lowered their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a report on Thursday, December 14th. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.